- Parent company: Opexa Therapeutics.
- T-cell vaccine given via subcutaneous injections every four weeks.
- Works similarly to a vaccine for a virus or bacteria; myelin-attacking cells are removed from a small amount of the patient's blood; these cells are inactivated and then injected back into the patient; the immune system is stimulated to potentially recognize and eliminate the inactivated cells and the same attacking cells not removed from the blood.
- TERMS is a placebo-controlled study being conducted at 40 sites in the United States with CIS and RRMS patients.
- Recruitment of 150 patients for this phase IIb study expected to be complete by mid-year (2007).
- TERMS is one of three ongoing studies using the current vaccine
Patients completing the one-year trial may participate in an open-label, one-year extension study where all patients would receive Tovaxin.